Oncbiomune Pharmaceuticals Inc. (OBMP) 0.1800 $OBM
Post# of 273242
Posted On: 09/19/2016 3:08:32 PM
Oncbiomune Pharmaceuticals Inc. (OBMP) 0.1800 $OBMP
OncBioMune Pharmaceuticals in Discussions to Acquire Vitel Laboratorios, S.A. de C.V.
Marketwire Canada - Wed Sep 14, 6:01AM CDT
BATON ROUGE, LA--(Marketwired - September 14, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that it is in discussions to acquire Vitel Laboratorios S.A. de C.V. ("Vitel" , a Mexico-based pharmaceutical company that develops and commercializes high specialty drugs in Mexico and other Latin American countries.
Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine
Marketwired - Mon Aug 08, 6:00AM CDT
BATON ROUGE, LA--(Marketwired - August 08, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to provide the latest information from the Phase 1 clinical trial evaluating the Company's novel cancer vaccine, ProscaVax, in PSA (Prostate Specific Antigen) recurrent prostate cancer in both hormone-naïve and hormone-independent patients. The trial is being hosted at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California under an IND from the U.S. Food and Drug Administration with funding from the U.S. Navy Cancer Vaccine Program.
Mexican Regulatory Authorities Supportive of OncBioMune's Phase 2 of ProscaVax for Prostate Cancer
Marketwire Canada - Thu Jun 02, 7:30AM CDT
BATON ROUGE, LA--(Marketwired - June 02, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to provide shareholders information on the Joint Venture in Mexico with Vitel Laboratorios S.A. de C.V. ("Vitel" for the development of the Company's novel cancer vaccine, ProscaVax, for the treatment of prostate cancer. A Phase 2 trial of ProscaVax is being prepared with expectations for commencement in the third quarter this year in PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients.
OncBioMune Pharmaceuticals to Present at the LD Micro Invitational
ACCESSWIRE - Wed Jun 01, 3:16PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 1, 2016 / OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, announced that it will be presenting at the 6th annual LD Micro Invitational on Wednesday, June 8 at 2:30 PM PST / 5:30 PM EST. Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune, will be giving the presentation and meeting with investors.
OncBioMune Receives Patent on Paclitaxel-Gallium-Transferrin for Targeted Cancer Treatment
Marketwired - Tue May 24, 7:02AM CDT
BATON ROUGE, LA--(Marketwired - May 24, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that it has been granted US Patent # 9,333,189 B2 on May 10, 2016 from the U.S. Patent and Trademark Office (USPTO), titled "Taxane-and taxoid-protein compositions."
Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer
Marketwire Canada - Wed May 18, 7:02AM CDT
BATON ROUGE, LA--(Marketwired - May 18, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to share with shareholders the recent comments received by the Company from the doctors overseeing the upcoming Phase 2 trial of ProscaVax in Mexico.
Celldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines
PR Newswire - Thu May 12, 12:49PM CDT
By Sara Bowman, Senior Writer, Online Media Group, Inc.
MRK: 61.52 (-0.76), GSK: 43.35 (+0.47)
OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
Marketwire Canada - Wed May 11, 8:10AM CDT
BATON ROUGE, LA--(Marketwired - May 11, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today provides shareholders with an update on the clinical advancement of ProscaVax, the Company's novel cancer vaccine in development for prostate cancer.
OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
Marketwire Canada - Wed May 04, 7:30AM CDT
BATON ROUGE, LA--(Marketwired - May 04, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that the protocol has been submitted to the Principal Investigator for the planned Phase 2 clinical trial to be hosted by a major university in the Northeast United States and its network of cancer centers. Glenn J. Bubley, MD, Director of Genitourinary Oncology at Beth Israel Deaconess Medical Center who has agreed to serve as the trial's Principal Investigator, is currently reviewing the documentation for submission to the U.S. Food and Drug Administration ("FDA" .
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in China
Marketwired - Thu Apr 28, 7:01AM CDT
OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notification on Grant of Patent Right for Invention No. 201080005114.4 from China's State Intellectual Property Office. The patent covers ProscaVax, OncBioMune's novel cancer vaccine currently in a Phase 1 trial for relapsed prostate cancer patients with bio chemical recurrence.
OncBioMune Enters Joint Venture, Preparation for Phase 2 Trial of Novel Cancer Vaccine for Prostate Cancer Underway
Marketwired - Wed Apr 20, 7:01AM CDT
OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the execution of the contract to form a Joint Venture ("JV" with Vitel Laboratorios S.A. de C.V. ("Vitel" for the purpose of developing and commercializing OncBioMune's portfolio of innovative cancer therapies in Mexico and Latin America. The documentation is being prepared to create the JV as a legal entity named OncBioMune Mexico S.A. de C.V. ("OncBioMune Mexico" . It has been agreed that Dr. Jonathan Head, Chief Executive Officer and Chairman of OncBioMune, will serve as Chief Executive Officer and President of OncBioMune Mexico. Manuel Cosme Odabachian, Chief Executive Officer of Vitel, will serve as Secretary of OncBioMune Mexico.
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in Hong Kong
Marketwired - Tue Apr 12, 10:13AM CDT
OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance for a patent on ProscaVax®, OncBioMune's cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from Hong Kong's patent office.
OncBioMune Invites Shareholders to Join Live Webcast Today at BIO CEO & Investors Conference
Marketwired - Tue Feb 09, 4:00AM CST
OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to invite shareholders and interested parties to listen live to the Company's presentation at the 2016 BIO CEO & Investor Conference at the Waldorf Astoria in New York, NY. Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will be presenting today at 3:30 PM ET in the Duke of Windsor room during the conference's Oncology Track. The presentation is being made available live at: http://www.veracast.com/webcasts/bio/ceoinvestor2016/7323119 6757.cfm.
OncBioMune Pharmaceuticals in Discussions to Acquire Vitel Laboratorios, S.A. de C.V.
Marketwire Canada - Wed Sep 14, 6:01AM CDT
BATON ROUGE, LA--(Marketwired - September 14, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that it is in discussions to acquire Vitel Laboratorios S.A. de C.V. ("Vitel" , a Mexico-based pharmaceutical company that develops and commercializes high specialty drugs in Mexico and other Latin American countries. Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine
Marketwired - Mon Aug 08, 6:00AM CDT
BATON ROUGE, LA--(Marketwired - August 08, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to provide the latest information from the Phase 1 clinical trial evaluating the Company's novel cancer vaccine, ProscaVax, in PSA (Prostate Specific Antigen) recurrent prostate cancer in both hormone-naïve and hormone-independent patients. The trial is being hosted at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California under an IND from the U.S. Food and Drug Administration with funding from the U.S. Navy Cancer Vaccine Program. Mexican Regulatory Authorities Supportive of OncBioMune's Phase 2 of ProscaVax for Prostate Cancer
Marketwire Canada - Thu Jun 02, 7:30AM CDT
BATON ROUGE, LA--(Marketwired - June 02, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to provide shareholders information on the Joint Venture in Mexico with Vitel Laboratorios S.A. de C.V. ("Vitel" for the development of the Company's novel cancer vaccine, ProscaVax, for the treatment of prostate cancer. A Phase 2 trial of ProscaVax is being prepared with expectations for commencement in the third quarter this year in PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients. OncBioMune Pharmaceuticals to Present at the LD Micro Invitational
ACCESSWIRE - Wed Jun 01, 3:16PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 1, 2016 / OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, announced that it will be presenting at the 6th annual LD Micro Invitational on Wednesday, June 8 at 2:30 PM PST / 5:30 PM EST. Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune, will be giving the presentation and meeting with investors. OncBioMune Receives Patent on Paclitaxel-Gallium-Transferrin for Targeted Cancer Treatment
Marketwired - Tue May 24, 7:02AM CDT
BATON ROUGE, LA--(Marketwired - May 24, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that it has been granted US Patent # 9,333,189 B2 on May 10, 2016 from the U.S. Patent and Trademark Office (USPTO), titled "Taxane-and taxoid-protein compositions." Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer
Marketwire Canada - Wed May 18, 7:02AM CDT
BATON ROUGE, LA--(Marketwired - May 18, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to share with shareholders the recent comments received by the Company from the doctors overseeing the upcoming Phase 2 trial of ProscaVax in Mexico. Celldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines
PR Newswire - Thu May 12, 12:49PM CDT
By Sara Bowman, Senior Writer, Online Media Group, Inc.
MRK: 61.52 (-0.76), GSK: 43.35 (+0.47)
OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
Marketwire Canada - Wed May 11, 8:10AM CDT
BATON ROUGE, LA--(Marketwired - May 11, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today provides shareholders with an update on the clinical advancement of ProscaVax, the Company's novel cancer vaccine in development for prostate cancer. OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
Marketwire Canada - Wed May 04, 7:30AM CDT
BATON ROUGE, LA--(Marketwired - May 04, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that the protocol has been submitted to the Principal Investigator for the planned Phase 2 clinical trial to be hosted by a major university in the Northeast United States and its network of cancer centers. Glenn J. Bubley, MD, Director of Genitourinary Oncology at Beth Israel Deaconess Medical Center who has agreed to serve as the trial's Principal Investigator, is currently reviewing the documentation for submission to the U.S. Food and Drug Administration ("FDA" . OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in China
Marketwired - Thu Apr 28, 7:01AM CDT
OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notification on Grant of Patent Right for Invention No. 201080005114.4 from China's State Intellectual Property Office. The patent covers ProscaVax, OncBioMune's novel cancer vaccine currently in a Phase 1 trial for relapsed prostate cancer patients with bio chemical recurrence. OncBioMune Enters Joint Venture, Preparation for Phase 2 Trial of Novel Cancer Vaccine for Prostate Cancer Underway
Marketwired - Wed Apr 20, 7:01AM CDT
OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the execution of the contract to form a Joint Venture ("JV" with Vitel Laboratorios S.A. de C.V. ("Vitel" for the purpose of developing and commercializing OncBioMune's portfolio of innovative cancer therapies in Mexico and Latin America. The documentation is being prepared to create the JV as a legal entity named OncBioMune Mexico S.A. de C.V. ("OncBioMune Mexico" . It has been agreed that Dr. Jonathan Head, Chief Executive Officer and Chairman of OncBioMune, will serve as Chief Executive Officer and President of OncBioMune Mexico. Manuel Cosme Odabachian, Chief Executive Officer of Vitel, will serve as Secretary of OncBioMune Mexico. OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in Hong Kong
Marketwired - Tue Apr 12, 10:13AM CDT
OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance for a patent on ProscaVax®, OncBioMune's cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from Hong Kong's patent office. OncBioMune Invites Shareholders to Join Live Webcast Today at BIO CEO & Investors Conference
Marketwired - Tue Feb 09, 4:00AM CST
OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to invite shareholders and interested parties to listen live to the Company's presentation at the 2016 BIO CEO & Investor Conference at the Waldorf Astoria in New York, NY. Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will be presenting today at 3:30 PM ET in the Duke of Windsor room during the conference's Oncology Track. The presentation is being made available live at: http://www.veracast.com/webcasts/bio/ceoinvestor2016/7323119 6757.cfm. 
(0)
(0)Scroll down for more posts ▼